

There's a life behind every test

The BD Veritor™ Plus System simplifies COVID-19* testing at the point of care

Discover the portable, easy-to-use BD Veritor™ Plus System. It provides reliable results in just 15 minutes.



*EUA Authorized by FDA



Simplifying COVID-19 testing

COVID-19 (SARS-CoV-2)

When your patients need reliable, rapid COVID-19 testing, turn to the **BD Veritor™ Plus System**. It offers dependable results at the point of care in a simple-to-operate portable instrument.



Simplifies the testing process

- Helps reduce manual test processing errors with its easy operation and single-button functionality
- Provides intuitive sample processing with prefilled, unitized tubes



Achieves reliable, rapid results

- Displays easy-to-read digital results for COVID-19 in 15 minutes¹:
 - » “CoV2: +” for positive; “CoV2: -” for negative
- Provides clear, objective results by correcting for nonspecific binding and detecting positives not recognized by the unaided eye¹



Delivers workflow efficiency

- Adapts easily to your workflow by offering 2 operational modes
 - » **Walk Away:** the test device is inserted immediately into the Analyzer so staff can multitask while the sample incubates (15 minutes)
 - » **Analyze Now:** the test device is inserted after the incubation time is complete, allowing batches of samples to be tested at once (results in seconds)



Provides result traceability

- Stores or downloads the lot number, patient/specimen ID, operator ID and test records using the BD Veritor™ InfoWiFi module or via the companion ImageMover application
- Offers result printing capabilities via USB port


Reference: 1. BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2. Package insert. 500048916 Becton, Dickinson and Company.

BD Life Sciences, 7 Loveton Circle, Sparks, MD 21152-0999 USA
800-638-8663

[BDVeritor.com](https://www.bdveritor.com)

BD, the BD Logo and Veritor are trademarks of Becton, Dickinson and Company or its affiliates. © 2023 BD. All rights reserved. (BD-26924 1164-US-0921 March 2023)

Clinical performance vs RT-PCR¹

	PPA [†]	NPA [‡]	Results in
COVID-19 (SARS-CoV-2)	84% (95% CI, 67%-93%)	100% (95% CI, 98%-100%)	 15
<small>†positive percent agreement ‡negative percent agreement</small>		COVID-19 results in 15 minutes	

Empower your staff with the BD Veritor™ Plus eLearning platform

- Assign customized training plans by role, product or learning type
- Simplify learning with 5-minute modules
- Easily track training compliance and competency assessments

Ordering information	Cat no.	Qty
BD Veritor™ Plus System SARS-CoV-2 Kit	256082	30 tests
BD Veritor™ Plus Analyzer	256066	1 unit

*EUA Information for the BD Veritor™ SARS-CoV-2 and SARS-CoV-2 & Flu A+B assays: These products have not been FDA cleared or approved; but have been authorized by FDA under EUA for use by authorized laboratories. The BD Veritor™ System for Rapid Detection of SARS-CoV-2 has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; the BD Veritor™ System for Rapid Detection of SARS-CoV-2 & Flu A+B has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens; and, the emergency use of these products is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

